Republican opposition to Califf over the agency’s recent move to relax its Mifeprex restrictions is ominous since in order be confirmed as FDA commissioner he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to the drug industry.
The Senate Health Committee voted 13-8 on 13 January to advance Robert Califf’s nomination to lead the US Food and Drug Administration. The positive but close vote sharply contrasted with his unanimous committee vote when he was confirmed to lead FDA under President Barack Obama and is indicative of a much tougher fight Califf is likely to face on the Senate floor this go round.
A key stumbling block appears to be FDA’s recent action to make it easier for people to access the abortion...
Lawmakers should address FDA staff upheaval and help the agency “get back on track,” former agency Chief of Staff Elizabeth Jungman said, while CBER Director Vinay Prasad told staff he is asking ex-colleagues to return to the agency.
NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.
A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
